Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial

Overview

Journal Transgend Health

Date 2024 Feb 5

PMID 38312459

Authors

Michelle S Cespedes

Moupali Das

Jenna Yager

Maria Prins

Ivanka Krznaric

Jan De Jong

Deqing Xiao

Yongwu Shao

Pamela Wong

Alexander Kintu

Christoph Carter

Elske Hoornenborg

Peter Ruane

John Phoenix

Islam Younis

Jason Halperin

Affiliations

Soon will be listed here.

Abstract

Purpose: Transgender women are disproportionately affected by HIV and are underutilizing preexposure prophylaxis (PrEP). The lower uptake of PrEP by transgender women may be, in part, owing to the perception that taking PrEP may lower the efficacy of gender-affirming hormone therapy (GAHT) or to provider concerns that GAHT may lower the efficacy of PrEP.

Methods: DISCOVER was a randomized, double-blind, noninferiority trial comparing emtricitabine (FTC, F) and tenofovir alafenamide (F/TAF) versus emtricitabine and tenofovir disoproxil fumarate (F/TDF) as PrEP among transgender women and cisgender men who have sex with men (MSM). This nested substudy of the DISCOVER trial compared the exposure of the active intracellular metabolites of FTC and tenofovir (TFV), FTC triphosphate (FTC-TP) and TFV diphosphate (TFV-DP), in peripheral blood mononuclear cells (PBMC) among transgender women receiving GAHT versus MSM within the F/TAF and F/TDF groups.

Results: Our results demonstrate that TFV-DP and FTC-TP levels in PBMC were comparable between transgender women on GAHT and MSM receiving F/TAF, and between transgender women on GAHT and MSM receiving F/TDF. TFV-DP concentrations remained above the EC of 40 fmol/10 cells across all groups. No clinically significant drug-drug interactions of GAHT were observed with either F/TAF or F/TDF in this subanalysis.

Conclusions: These findings are consistent with the clinical pharmacology of GAHT, FTC, TDF, and TAF reported in previous studies, and support the continued use of F/TAF and F/TDF for PrEP in transgender women.

Citing Articles

Social, economic, and physical side effects impact PrEP uptake and persistence among transgender women in Peru.

Naz-McLean S, Clark J, Huerta L, Mayer K, Lama J, Reisner S BMC Public Health. 2024; 24(1):1985.

PMID: 39054504 PMC: 11270771. DOI: 10.1186/s12889-024-19474-x.

Awareness and utilization of pre-exposure prophylaxis and HIV prevention services among transgender and non-binary adolescent and young adults.

Rodriguez A, Horvath K, Dowshen N, Voss R, Warus J, Jacobs M Front Reprod Health. 2024; 5:1150370.

PMID: 38318604 PMC: 10839107. DOI: 10.3389/frph.2023.1150370.

Providing gender-affirming care to transgender and gender-diverse individuals with and at risk for HIV.

Van Gerwen O, Blumenthal J Top Antivir Med. 2023; 31(1):3-13.

PMID: 37018731 PMC: 10089290.

Mapping Community-Engaged Implementation Strategies with Transgender Scientists, Stakeholders, and Trans-Led Community Organizations.

Restar A, Minalga B, Quilantang M, Adamson T, Dusic E, van der Merwe L Curr HIV/AIDS Rep. 2023; 20(3):160-169.

PMID: 37012537 PMC: 10071255. DOI: 10.1007/s11904-023-00656-y.

Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention.

Abdool Karim Q, Archary D, Barre-Sinoussi F, Broliden K, Cabrera C, Chiodi F Front Immunol. 2022; 13:1055042.

PMID: 36561760 PMC: 9763292. DOI: 10.3389/fimmu.2022.1055042.

References

Klein A, Golub S . Increasing Access to Pre-Exposure Prophylaxis Among Transgender Women and Transfeminine Nonbinary Individuals. AIDS Patient Care STDS. 2019; 33(6):262-269. DOI: 10.1089/apc.2019.0049. View

Perez-Brumer A, Naz-McLean S, Huerta L, Salazar X, Lama J, Sanchez J . The wisdom of mistrust: qualitative insights from transgender women who participated in PrEP research in Lima, Peru. J Int AIDS Soc. 2021; 24(9):e25769. PMC: 9936804. DOI: 10.1002/jia2.25769. View

Anderson P, Glidden D, Liu A, Buchbinder S, Lama J, Guanira J . Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012; 4(151):151ra125. PMC: 3721979. DOI: 10.1126/scitranslmed.3004006. View

Yager J, Brooks K, Brothers J, Mulligan K, Landovitz R, Reirden D . Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate. AIDS Res Hum Retroviruses. 2022; 38(12):939-943. PMC: 9910105. DOI: 10.1089/AID.2022.0044. View

Koeplinger K, Raub T, Padbury G, Zhao Z . Equilibrium distribution of HIV antiviral drugs into human peripheral blood mononuclear cells (PBMC) is controlled by free drug concentration in the extracellular medium. J Pharm Biomed Anal. 2000; 19(3-4):399-411. DOI: 10.1016/s0731-7085(98)00143-5. View

Lai J, Wang J, Cai Z . Nucleoside reverse transcriptase inhibitors and their phosphorylated metabolites in human immunodeficiency virus-infected human matrices. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 868(1-2):1-12. DOI: 10.1016/j.jchromb.2008.04.012. View

Krakower D . Human Immunodeficiency Virus Preexposure Prophylaxis: Meeting the Needs of Transgender Populations. Clin Infect Dis. 2020; 73(7):e2124-e2126. DOI: 10.1093/cid/ciaa1158. View

Kearney B, Mathias A . Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacotherapy. 2009; 29(8):924-9. DOI: 10.1592/phco.29.8.924. View

Estcourt C, Yeung A, Nandwani R, Goldberg D, Cullen B, Steedman N . Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM. AIDS. 2020; 35(4):665-673. PMC: 7924973. DOI: 10.1097/QAD.0000000000002790. View

10.

Birkus G, Wang R, Liu X, Kutty N, MacArthur H, Cihlar T . Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother. 2006; 51(2):543-50. PMC: 1797775. DOI: 10.1128/AAC.00968-06. View

11.

Baral S, Poteat T, Stromdahl S, Wirtz A, Guadamuz T, Beyrer C . Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 13(3):214-22. DOI: 10.1016/S1473-3099(12)70315-8. View

12.

Xiao D, Ling K, Tarnowski T, Majeed S, Kearney B, Kolaris C . The determination of human peripheral blood mononuclear cell counts using a genomic DNA standard and application in tenofovir diphosphate quantitation. Anal Biochem. 2019; 585:113399. DOI: 10.1016/j.ab.2019.113399. View

13.

Lee W, He G, Eisenberg E, Cihlar T, Swaminathan S, Mulato A . Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005; 49(5):1898-906. PMC: 1087627. DOI: 10.1128/AAC.49.5.1898-1906.2005. View

14.

Crommentuyn K, Huitema A, Beijnen J . Bioanalysis of HIV protease inhibitors in samples from sanctuary sites. J Pharm Biomed Anal. 2005; 38(1):139-47. DOI: 10.1016/j.jpba.2004.12.012. View

15.

Sevelius J, Keatley J, Calma N, Arnold E . 'I am not a man': Trans-specific barriers and facilitators to PrEP acceptability among transgender women. Glob Public Health. 2016; 11(7-8):1060-75. PMC: 10204128. DOI: 10.1080/17441692.2016.1154085. View

16.

Poteat T, Wirtz A, Malik M, Cooney E, Cannon C, Hardy W . A Gap Between Willingness and Uptake: Findings From Mixed Methods Research on HIV Prevention Among Black and Latina Transgender Women. J Acquir Immune Defic Syndr. 2019; 82(2):131-140. PMC: 7807529. DOI: 10.1097/QAI.0000000000002112. View

17.

Wood S, Gross R, Shea J, Bauermeister J, Franklin J, Petsis D . Barriers and Facilitators of PrEP Adherence for Young Men and Transgender Women of Color. AIDS Behav. 2019; 23(10):2719-2729. PMC: 6790163. DOI: 10.1007/s10461-019-02502-y. View

18.

Ivetac A, McCammon J . Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations. J Mol Biol. 2009; 388(3):644-58. PMC: 2744402. DOI: 10.1016/j.jmb.2009.03.037. View

19.

Durand-Gasselin L, Da Silva D, Benech H, Pruvost A, Grassi J . Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. Antimicrob Agents Chemother. 2007; 51(6):2105-11. PMC: 1891370. DOI: 10.1128/AAC.00831-06. View

20.

Shieh E, Marzinke M, Fuchs E, Hamlin A, Bakshi R, Aung W . Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. J Int AIDS Soc. 2019; 22(11):e25405. PMC: 6832671. DOI: 10.1002/jia2.25405. View